Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Eloxx Pharmaceuticals Q3 2026 Results: Net Loss of $5.54M, Loss Widens

Eloxx Pharmaceuticals is a clinical-stage biotechnology company focused on developing exaluren for Alport Syndrome and ADPKD. The company reports significant operating losses and indicates a substantial need for additional funding to continue as a going concern and maintain its Nasdaq listing.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-5.5-0.4
EPS (diluted, $ a share)$-0.49$-0.58

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ELOX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Eloxx Pharmaceuticals, Inc.: key numbers

Share price
$11.74Close, Nov 17
Market cap
$48M
Shares outstanding
4.09MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Eloxx Pharmaceuticals, Inc.

All →
9:03 AM ET 8-K
Financial Results

Eloxx Pharmaceuticals Financial Results

Eloxx Pharmaceuticals reported Q3 2026 financial results and provided a business update on its rare kidney disease pipeline, including the dosing of the first two patients in the Phase 2b EXACT study for Alport syndrome. The company also received FDA IND clearance for its Phase 2 EXPRESS study in ADPKD and ended the quarter with $56.3 million in cash.

Term
Q3 2026

“The third quarter marked important progress for Eloxx, as we dosed the first two patients in our Phase 2b EXACT study in nonsense mutation Alport syndrome. With the EXPRESS protocol finalized and IND clearance in hand, we now have two programs in rare kidney disease.”

Sumit Aggarwal, President and Chief Executive Officer
6:01 AM ET 8-K
Leadership Change

Eloxx Pharmaceuticals Leadership Change

Eloxx Pharmaceuticals has expanded its Board of Directors from five to six members and appointed Geno J. Germano as an independent director. Mr. Germano is a 35-year pharmaceutical industry veteran who previously served as CEO of Elucida Oncology and Group President at Pfizer. He will serve a term expiring at the company's 2027 annual meeting of stockholders.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.